Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum

Ionis Pharmaceuticals Inc. ((IONS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Ionis Pharmaceuticals’ latest earnings call struck an upbeat tone, with management emphasizing strong revenue growth, successful drug launches, and pivotal clinical wins that support multibillion‑dollar peak sales potential. While executives acknowledged regulatory, pricing, and execution risks, they framed these as manageable near‑term bumps against a backdrop of accelerating commercial and pipeline momentum.

Broad‑Based Revenue Growth Signals Business Maturity

Ionis reported 2025 revenue of $944 million, a 34% year‑over‑year increase driven by both marketed medicines and R&D collaborations. The balanced mix shows the company evolving from a pure development story into a more diversified commercial biopharma platform with multiple income streams.

TRYNGOLZA Builds Launch Momentum Ahead of sHTG Expansion

TRYNGOLZA delivered $108 million in 2025 product sales, with Q4 contributing $50 million and growing 56% sequentially. Management highlighted December as the strongest month of the year and a payer mix of roughly 60% commercial and 40% government, underscoring early demand and broad market access.

DAWNZERA Shows Promising Early Uptake and Strong Conversion

DAWNZERA generated $8 million in 2025 sales from just the initial launch period, supported by a robust free‑trial program. Notably, the company reported 100% conversion from free trial to paid therapy so far and reiterated confidence in peak sales potential above $500 million.

Olezarsen’s Phase III Data Reshape the sHTG Landscape

In its pivotal CORE and CORE2 trials, olezarsen achieved up to a 72% mean placebo‑adjusted reduction in fasting triglycerides at six months. More importantly for payers and clinicians, the drug cut adjudicated acute pancreatitis events by 85% and showed a number needed to treat of just four in the highest‑risk subgroup.

Regulatory Path Advances for Olezarsen With Launch in Sight

Olezarsen has received Breakthrough Therapy designation, and the company has submitted an sNDA with commercial launch readiness targeted by June. Ionis is positioning the medicine as a potential >$2 billion opportunity in severe hypertriglyceridemia, while guidance conservatively assumes a standard rather than priority review.

Zilganersen Delivers First Disease‑Modifying Benefit in Alexander Disease

Zilganersen’s Phase III trial produced positive results showing the first disease‑modifying effect in Alexander disease, a rare neurodegenerative condition. Ionis filed an NDA in January and is preparing for a potential approval and launch in the second half of 2026, including an expanded access program to bridge high‑need patients.

Partner Pipeline Adds Upside With Bepirovirsen and Late‑Stage Assets

Partnered programs added meaningful value, highlighted by bepirovirsen’s Phase III data showing unprecedented functional cure rates in chronic hepatitis B. GSK is preparing global regulatory submissions and commercialization later this year, while other key partner readouts, including pelacarsen and CARDIO‑TTRansform, are slated for 2026.

Diverse Revenue Mix and Growing Royalty Base

Commercial products contributed $436 million, or 46% of total revenue, while R&D collaborations delivered $508 million, or 54%. Royalty revenue climbed 11% to $285 million, driven by the durability of SPINRAZA and expanding WAINUA royalties, supporting a more resilient financial profile.

Solid Balance Sheet Supports Investment and Long‑Term Goals

Ionis projects year‑end 2026 cash and investments of about $1.6 billion after repaying its remaining 2026 convertible notes. Management framed guidance as implying roughly 20% like‑for‑like revenue growth in 2026 and reiterated a public goal of reaching cash‑flow breakeven by 2028, balancing growth spend with discipline.

Commercial Infrastructure Scales for Multiple Independent Launches

The company now has a full commercial field force with around 200 representatives hired, trained, and deployed across key markets. This infrastructure is being leveraged for TRYNGOLZA and DAWNZERA and readied for two additional independent launches in 2026, namely olezarsen in sHTG and zilganersen.

Conservative Guidance Around Olezarsen Review Timing

Management stressed that 2026 guidance assumes a standard FDA review for olezarsen, implying a potential Q4 approval in sHTG. This cautious posture effectively pushes broader revenue contribution into late 2026 or beyond, leaving upside if priority review is granted or uptake exceeds initial expectations.

TRYNGOLZA Revenue Dip Expected Before sHTG Reacceleration

Despite strong 2025 trends, Ionis projects a meaningful decline in TRYNGOLZA revenue across 2026 as pricing negotiations and transition planning unfold. Executives expect sales to reaccelerate after the sHTG approval and launch, as the label broadens and prescribing patterns normalize under the new framework.

Operating Loss Persists as Commercial Investments Ramp

The company guided to a 2026 non‑GAAP operating loss of $500 million to $550 million, similar to 2025 on a comparable basis excluding a one‑time license fee. Operating expenses are expected to rise in the low‑teens percent range, reflecting continued investment in launches and late‑stage pipeline programs rather than cost cutting.

Debt Repayment Tightens Liquidity but De‑Risks Capital Structure

Ionis plans to use $433 million of cash to retire its remaining 2026 convertible notes, a move already reflected in year‑end cash guidance. While this reduces near‑term liquidity, it simplifies the balance sheet and removes potential overhang from conversion or refinancing over the next year.

Regulatory and Clinical Milestones Carry Binary Risk

Management flagged uncertainties around olezarsen’s review designation, noting that priority review is not guaranteed and remains in the FDA’s hands. The company also acknowledged that major upcoming readouts, such as the HORIZON Lp(a) cardiovascular outcome study, carry first‑to‑test risk for the broader Lp(a) hypothesis.

Pricing and Competitive Dynamics Remain a Moving Target

Ionis noted that market pricing is evolving, citing competitive references and ongoing payer discussions that could pressure near‑term revenue. Final pricing decisions for key therapies have yet to be locked in, and management is signaling a willingness to adjust to secure broad access and long‑term share.

Partner Contributions Understated in Near‑Term Guidance

Despite strong late‑stage data from assets like bepirovirsen, Ionis has embedded only modest partner milestone and royalty contributions into its 2026 outlook. Many of these potential inflows are expected to fall in late 2026 or beyond, creating room for upside versus current expectations if timelines and launches go smoothly.

Guidance Frames 2026 as a Transition Year With Upside

For 2026, Ionis guided revenue to $800 million to $825 million, reflecting about 20% like‑for‑like growth when stripping out a prior one‑time license payment. The company expects low‑teens operating expense growth, a non‑GAAP operating loss of $500 million to $550 million, stable R&D spend, roughly $1.6 billion in year‑end cash post‑debt repayment, and a path to cash‑flow breakeven by 2028.

Ionis’ earnings call painted a picture of a company in transition from platform story to commercial growth engine, with multiple successful launches and high‑impact clinical data leading the way. While investors must navigate near‑term revenue noise, pricing debates, and binary readouts, the underlying trajectory points toward expanding revenue, derisked assets, and increasing long‑term value creation potential.